Camlin Fine Sciences Limited
Valuation (39/100) does the heavy lifting; momentum (9/100) is the drag.
Buy zoneSolvency riskOur blended model reads Camlin Fine Sciences Limited as a Strong Sell at 22/100. At ₹127.74 it trades above our blended DCF and relative-multiples fair value of ₹99.16, about 22% downside to that estimate — we read it as overvalued by 22%. On 17.0x trailing earnings it sits cheaper than the Basic Materials median of about 22.2x. The price is about 53% below its 52-week high of ₹272.6 and 32% above the low of ₹96.93. Financial health scores 29/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹177.5 implies about 39% upside across 2 analysts. It clears 1 of 12 investability checks, with durability 17, valuation 65 and momentum 9 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹79.33.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-53.14% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Sell22Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: -3.4%
- Fail: Low debt (D/E < 0.5): 0.72x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -3%
- No data: Earnings growing
- Fail: Net margin ≥ 10%: 1.6%
- Fail: Current ratio > 1.5: 1.27
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 2.14
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter44.1%
- Institutions17.2%
- Public & other38.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Trading in our value buy zone versus sector peers.
- Well off its 52-week high — possible mean-reversion.
Bear case
Weaknesses
- Low return on equity (-3.4%).
- Price below its 200-day moving average (downtrend).
Threats
- Trades ~22% above our estimated fair value.
About Camlin Fine Sciences Limited
Camlin Fine Sciences Limited researches, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products across India and international markets. Its product portfolio includes shelf-life solutions such as antioxidants (TBHQ, BHA, BHT, and ASP) and aroma ingredients including vanillin and ethyl vanillin.
Camlin Fine Sciences Limited — frequently asked questions
Is Camlin Fine Sciences Limited a buy, hold or sell?
StocksWizard currently rates Camlin Fine Sciences Limited (CAMLINFINE) a Strong Sell, based on a blended score of 22/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Camlin Fine Sciences Limited's fair value?
Our blended DCF and relative-valuation model estimates Camlin Fine Sciences Limited's fair value at about ₹99.16, versus a current price of ₹127.74 — roughly 22% downside. On that basis the stock looks overvalued by 22%.
Is Camlin Fine Sciences Limited financially healthy?
Camlin Fine Sciences Limited scores 29/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Camlin Fine Sciences Limited's share price performed?
Camlin Fine Sciences Limited is down 2% over three months, and last traded at ₹127.74. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.